Protocol for tumour-focused dose-escalated adaptive radiotherapy for the radical treatment of bladder cancer in a multicentre phase II randomised controlled trial (RAIDER): radiotherapy planning and delivery guidance

Shaista Hafeez, Amanda Webster, Vibeke N Hansen, Helen A McNair, Karole Warren-Oseni, Emma Patel, Ananya Choudhury, Joanne Creswell, Farshad Foroudi, Ann Henry, Tomas Kron, Duncan B McLaren, Anita V Mitra, Hugh Mostafid, Daniel Saunders, Elizabeth Miles, Clare Griffin, Rebecca Lewis, Emma Hall, Robert Huddart, Shaista Hafeez, Amanda Webster, Vibeke N Hansen, Helen A McNair, Karole Warren-Oseni, Emma Patel, Ananya Choudhury, Joanne Creswell, Farshad Foroudi, Ann Henry, Tomas Kron, Duncan B McLaren, Anita V Mitra, Hugh Mostafid, Daniel Saunders, Elizabeth Miles, Clare Griffin, Rebecca Lewis, Emma Hall, Robert Huddart

Abstract

Introduction: Daily radiotherapy delivered with radiosensitisation offers patients with muscle invasive bladder cancer (MIBC) comparable outcomes to cystectomy with functional organ preservation. Most recurrences following radiotherapy occur within the bladder. Increasing the delivered radiotherapy dose to the tumour may further improve local control. Developments in image-guided radiotherapy have allowed bladder tumour-focused 'plan of the day' radiotherapy delivery. We aim to test within a randomised multicentre phase II trial whether this technique will enable dose escalation with acceptable rates of toxicity.

Methods and analysis: Patients with T2-T4aN0M0 unifocal MIBC will be randomised (1:1:2) between standard/control whole bladder single plan radiotherapy, standard dose adaptive tumour-focused radiotherapy or dose-escalated adaptive tumour-focused radiotherapy (DART). Adaptive tumour-focused radiotherapy will use a library of three plans (small, medium and large) for treatment. A cone beam CT taken prior to each treatment will be used to visualise the anatomy and inform selection of the most appropriate plan for treatment.Two radiotherapy fractionation schedules (32f and 20f) are permitted. A minimum of 120 participants will be randomised in each fractionation cohort (to ensure 57 evaluable DART patients per cohort).A comprehensive radiotherapy quality assurance programme including pretrial and on-trial components is instituted to ensure standardisation of radiotherapy planning and delivery.The trial has a two-stage non-comparative design. The primary end point of stage I is the proportion of patients meeting predefined normal tissue constraints in the DART group. The primary end point of stage II is late Common Terminology Criteria for Adverse Events grade 3 or worse toxicity aiming to exclude a rate of >20% (80% power and 5% alpha, one sided) in each DART fractionation cohort. Secondary end points include locoregional MIBC control, progression-free survival overall survival and patient-reported outcomes.

Ethics and dissemination: This clinical trial is approved by the London-Surrey Borders Research Ethics Committee (15/LO/0539). The results when available will be disseminated via peer-reviewed scientific journals, conference presentations and submission to regulatory authorities.

Trial registration number: NCT02447549; Pre-results.

Keywords: clinical trials; oncology; radiotherapy; urological tumours.

Conflict of interest statement

Competing interests: SH reports non-financial support from Elekta (Elekta AB, Stockholm, Sweden), non-financial support from Merck Sharp & Dohme (MSD), personal fees and non-financial support from Roche outside the submitted work; AC reports grants from National Institute of Health Research Manchester Biomedical Research Centre, grants from Cancer Research, UK, grants from Medical Research Council, UK, grants from Prostate Cancer, UK, grants from Bayer, UK, personal fees from Janssen Pharmaceutical, non-financial support from ASCO, grants and non-financial support from Elekta AB, outside the submitted work; AH reports grants from CRUK, grants from MRC, grants from NIHR, outside the submitted work; TK reports reports grants from Cancer Australia, during the conduct of the study; and his group has a research collaborative agreement with Varian Medical System not related to this project; EH reports grants from Cancer Research UK during the conduct of the study; grants from Accuray Inc., grants from Varian Medical Systems Inc., outside the submitted work; RH reports non-financial support from Janssen, grants and personal fees from MSD, personal fees from Bristol Myers Squibb, grants from Cancer Research UK, other from Nektar Therapeutics, personal fees and non-financial support from Roche outside the submitted work.

© Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY. Published by BMJ.

Figures

Figure 1
Figure 1
Trial schema. f, fraction; PRO, patient-reported outcome; RTOG, Radiation Therapy Oncology Group.

References

    1. National Institute for Health and Clinical Excellence (NICE) Guidance Bladder cancer: diagnosis and management, 2015. Available:
    1. James ND, Hussain SA, Hall E, et al. . Radiotherapy with or without chemotherapy in muscle-invasive bladder cancer. N Engl J Med 2012;366:1477–88. 10.1056/NEJMoa1106106
    1. Hoskin PJ, Rojas AM, Bentzen SM, et al. . Radiotherapy with concurrent carbogen and nicotinamide in bladder carcinoma. J Clin Oncol 2010;28:4912–8. 10.1200/JCO.2010.28.4950
    1. Bellmunt J, Orsola A, Leow JJ, et al. . Bladder cancer: ESMO practice guidelines for diagnosis, treatment and follow-up. Ann Oncol 2014;25 Suppl 3:iii40–8. 10.1093/annonc/mdu223
    1. Alfred Witjes J, Lebret T, Compérat EM, et al. . Updated 2016 EAU guidelines on muscle-invasive and metastatic bladder cancer. Eur Urol 2017;71:462–75. 10.1016/j.eururo.2016.06.020
    1. Hafeez S, Horwich A, Omar O, et al. . Selective organ preservation with neo-adjuvant chemotherapy for the treatment of muscle invasive transitional cell carcinoma of the bladder. Br J Cancer 2015;112:1626–35. 10.1038/bjc.2015.109
    1. Zietman AL, Grocela J, Zehr E, et al. . Selective bladder conservation using transurethral resection, chemotherapy, and radiation: management and consequences of TA, T1, and tis recurrence within the retained bladder. Urology 2001;58:380–5. 10.1016/S0090-4295(01)01219-5
    1. Majewski W, Maciejewski B, Majewski S, et al. . Clinical radiobiology of stage T2-T3 bladder cancer. Int J Radiat Oncol Biol Phys 2004;60:60–70. 10.1016/j.ijrobp.2004.02.056
    1. Steel G. Basic clinical radiobiology. 3rd edn Oxford University Press, 2002.
    1. Pos FJ, Hart G, Schneider C, et al. . Radical radiotherapy for invasive bladder cancer: what dose and fractionation schedule to choose? Int J Radiat Oncol Biol Phys 2006;64:1168–73. 10.1016/j.ijrobp.2005.09.023
    1. Fokdal L, Honoré H, Høyer M, et al. . Impact of changes in bladder and rectal filling volume on organ motion and dose distribution of the bladder in radiotherapy for urinary bladder cancer. Int J Radiat Oncol Biol Phys 2004;59:436–44. 10.1016/j.ijrobp.2003.10.039
    1. Lotz HT, Pos FJ, Hulshof MCCM, et al. . Tumor motion and deformation during external radiotherapy of bladder cancer. Int J Radiat Oncol Biol Phys 2006;64:1551–8. 10.1016/j.ijrobp.2005.12.025
    1. Meijer GJ, Rasch C, Remeijer P, et al. . Three-Dimensional analysis of delineation errors, setup errors, and organ motion during radiotherapy of bladder cancer. Int J Radiat Oncol Biol Phys 2003;55:1277–87. 10.1016/S0360-3016(02)04162-7
    1. Lalondrelle S, Huddart R, Warren-Oseni K, et al. . Adaptive-predictive organ localization using cone-beam computed tomography for improved accuracy in external beam radiotherapy for bladder cancer. Int J Radiat Oncol Biol Phys 2011;79:705–12. 10.1016/j.ijrobp.2009.12.003
    1. National radiotherapy implementation group report image guided radiotherapy (IGRT) guidance for implementation and use, 2012. Available:
    1. McDonald F, Lalondrelle S, Taylor H, et al. . Clinical implementation of adaptive hypofractionated bladder radiotherapy for improvement in normal tissue irradiation. Clin Oncol 2013;25:549–56. 10.1016/j.clon.2013.06.001
    1. Vestergaard A, Muren LP, Lindberg H, et al. . Normal tissue sparing in a phase II trial on daily adaptive plan selection in radiotherapy for urinary bladder cancer. Acta Oncol 2014;53:997–1004. 10.3109/0284186X.2014.928419
    1. Foroudi F, Wong J, Kron T, et al. . Online adaptive radiotherapy for muscle-invasive bladder cancer: results of a pilot study. Int J Radiat Oncol Biol Phys 2011;81:765–71. 10.1016/j.ijrobp.2010.06.061
    1. Tuomikoski L, Collan J, Keyriläinen J, et al. . Adaptive radiotherapy in muscle invasive urinary bladder cancer--an effective method to reduce the irradiated bowel volume. Radiother Oncol 2011;99:61–6. 10.1016/j.radonc.2011.02.011
    1. Huddart RA, Hall E, Hussain SA, et al. . Randomized noninferiority trial of reduced high-dose volume versus standard volume radiation therapy for muscle-invasive bladder cancer: results of the BC2001 trial (CRUK/01/004). Int J Radiat Oncol Biol Phys 2013;87:261–9. 10.1016/j.ijrobp.2013.06.2044
    1. Cowan RA, McBain CA, Ryder WDJ, et al. . Radiotherapy for muscle-invasive carcinoma of the bladder: results of a randomized trial comparing conventional whole bladder with dose-escalated partial bladder radiotherapy. Int J Radiat Oncol Biol Phys 2004;59:197–207. 10.1016/j.ijrobp.2003.10.018
    1. Caffo O, Thompson C, De Santis M, et al. . Concurrent gemcitabine and radiotherapy for the treatment of muscle-invasive bladder cancer: a pooled individual data analysis of eight phase I-II trials. Radiother Oncol 2016;121:193–8. 10.1016/j.radonc.2016.09.006
    1. Coppin CM, Gospodarowicz MK, James K, et al. . Improved local control of invasive bladder cancer by concurrent cisplatin and preoperative or definitive radiation. The National cancer Institute of Canada clinical Trials Group. J Clin Oncol 1996;14:2901–7. 10.1200/JCO.1996.14.11.2901
    1. International Committe on Radiation Units and Measurements ICRU report 83 prescribing, recording, and reporting intensity-modulated Photon-Beam therapy (IMRT), 2010.
    1. Hafeez S, McDonald F, Lalondrelle S, et al. . Clinical outcomes of image guided adaptive Hypofractionated Weekly radiation therapy for bladder cancer in patients unsuitable for radical treatment. Int J Radiat Oncol Biol Phys 2017;98:115–22. 10.1016/j.ijrobp.2017.01.239
    1. Dearnaley D, Syndikus I, Sumo G, et al. . Conventional versus hypofractionated high-dose intensity-modulated radiotherapy for prostate cancer: preliminary safety results from the CHHiP randomised controlled trial. Lancet Oncol 2012;13:43–54. 10.1016/S1470-2045(11)70293-5
    1. McDonald F, Waters R, Gulliford S, et al. . Defining bowel dose volume constraints for bladder radiotherapy treatment planning. Clin Oncol 2015;27:22–9. 10.1016/j.clon.2014.09.016
    1. Hafeez S, Warren-Oseni K, McNair HA, et al. . Prospective study delivering simultaneous integrated high-dose tumor boost (≤70 Gy) with image guided adaptive radiation therapy for radical treatment of localized muscle-invasive bladder cancer. Int J Radiat Oncol Biol Phys 2016;94:1022–30. 10.1016/j.ijrobp.2015.12.379
    1. Dale RG. The application of the linear-quadratic dose-effect equation to fractionated and protracted radiotherapy. Br J Radiol 1985;58:515–28. 10.1259/0007-1285-58-690-515
    1. Bese NS, Hendry J, Jeremic B. Effects of prolongation of overall treatment time due to unplanned interruptions during radiotherapy of different tumor sites and practical methods for compensation. Int J Radiat Oncol Biol Phys 2007;68:654–61. 10.1016/j.ijrobp.2007.03.010
    1. Hafeez S, Patel E, Webster A, et al. . Protocol for hypofractionated adaptive radiotherapy to the bladder within a multicentre phase II randomised trial: radiotherapy planning and delivery guidance. BMJ Open 2020;10:e037134. 10.1136/bmjopen-2020-037134
    1. Patel E, Tsang Y, Baker A, et al. . Quality assuring "Plan of the day" selection in a multicentre adaptive bladder trial: Implementation of a pre-accrual IGRT guidance and assessment module. Clin Transl Radiat Oncol 2019;19:27–32. 10.1016/j.ctro.2019.07.006
    1. Foroudi F, Pham D, Rolfo A, et al. . The outcome of a multi-centre feasibility study of online adaptive radiotherapy for muscle-invasive bladder cancer TROG 10.01 BOLART. Radiother Oncol 2014;111:316–20. 10.1016/j.radonc.2014.02.015

Source: PubMed

Sponsors et collaborateurs

Les conditions médicales

Interventions en matière de drogue

3
S'abonner